Neuropathic pain and cytokines: Current perspectives

Journal of Pain Research

Volumn 6, Issue , 2013, Pages 803-814

  Clark, Anna K ^a   Old, Elizabeth A ^a   Malcangio, Marzia ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Anti inflammatory cytokines; Astrocytes; First pain synapse; Microglia; Proinflammatory cytokines

Indexed keywords

ADAM10 ENDOPEPTIDASE; ANALGESIC AGENT; CHEMOKINE; CYTOKINE; ETANERCEPT; FRACTALKINE; GLATIRAMER; GLYCOPROTEIN GP 120; INFLAMMASOME; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 4; JANUS KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT INTERLEUKIN 10; STAT PROTEIN; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ASTROCYTE; CELL COMMUNICATION; CLINICAL MEDICINE; DRUG HALF LIFE; HUMAN; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MICROGLIA; MOUSE; NERVE CELL PLASTICITY; NEUROPATHIC PAIN; NOCICEPTIVE STIMULATION; NONHUMAN; PERIPHERAL NERVE INJURY; PERIPHERAL NERVOUS SYSTEM; PERIPHERAL NEUROPATHY; REVIEW; SOMATOSENSORY STIMULATION; SPINAL CORD NERVE CELL; T LYMPHOCYTE;

EID: 84888175082     PISSN: 11787090     EISSN: None     Source Type: Journal    
DOI: 10.2147/JPR.S53660     Document Type: Review

References (112)

1. Thacker MA, Clark AK, Marchand F, McMahon SB. Pathophysiology of peripheral neuropathic pain: immune cells and molecules. Anesth Analg. 2007;105(3):838-847.
2. Austin PJ, Moalem-Taylor G. The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like glial cells and cytokines. J Neuroimmunol. 2010;229(1-2):26-50.
3. McMahon SB, Malcangio M. Current challenges in glia-pain biology. Neuron. 2009;64(1):46-54.
4. Clark AK, Malcangio M. Microglial signalling mechanisms: Cathepsin S and Fractalkine. Exp Neurol. 2012;234(2):283-292.
5. Hansen RR, Malcangio M. Astrocytes-Multitaskers in chronic pain. Eur J Pharmacol. 2013;716(1-3):120-128.
6. Echeverry S, Shi XQ, Rivest S, Zhang J. Peripheral nerve injury alters blood-spinal cord barrier functional and molecular integrity through a selective inflammatory pathway. J Neurosci. 2011;31(30): 10819-10828.
7. Beggs S, Liu XJ, Kwan C, Salter MW. Peripheral nerve injury and TRPV1-expressing primary afferent C-fibers cause opening of the blood-brain barrier. Mol Pain. 2010;6:74.
8. Sweitzer SM, Hickey WF, Rutkowski MD, Pahl JL, DeLeo JA. Focal peripheral nerve injury induces leukocyte trafficking into the central nervous system: potential relationship to neuropathic pain. Pain. 2002;100(1-2):163-170.
9. Zhang J, Shi XQ, Echeverry S, Mogil JS, De Koninck Y, Rivest S. Expression of CCR2in both resident and bone marrow-derived microglia plays a critical role in neuropathic pain. J Neurosci. 2007;27(45):12396-12406.
10. Cao L, DeLeo JA. CNS-infiltrating CD4+ T lymphocytes contribute to murine spinal nerve transection-induced neuropathic pain. Eur J Immunol. 2008;38(2):448-458.
11. Costigan M, Moss A, Latremoliere A, etal. T-cell infiltration and signaling in the adult dorsal spinal cord is a major contributor to neuropathic pain-like hypersensitivity. J Neurosci. 2009;29(46):14415-14422.
12. Leger T, Grist J, D'Acquisto F, Clark AK, Malcangio M. Glatiramer acetate attenuates neuropathic allodynia through modulation of adaptive immune cells. J Neuroimmunol. 2011;234(1-2):19-26.
13. Dinarello CA. Historical insights into cytokines. Eur J Immunol. 2007;37 Suppl 1:S34-S45.
14. Honore P, Wade CL, Zhong C, etal. Interleukin-1alphabeta gene-deficient mice show reduced nociceptive sensitivity in models of inflammatory and neuropathic pain but not post-operative pain. Behav Brain Res. 2006;167(2):355-364.
15. Wolf G, Gabay E, Tal M, Yirmiya R, Shavit Y. Genetic impairment of interleukin-1signaling attenuates neuropathic pain, autotomy, and spontaneous ectopic neuronal activity, following nerve injury in mice. Pain. 2006;120(3):315-324.
16. Gabay E, Wolf G, Shavit Y, Yirmiya R, Tal M. Chronic blockade of interleukin-1 (IL-1) prevents and attenuates neuropathic pain behavior and spontaneous ectopic neuronal activity following nerve injury. Eur J Pain. 2011;15(3):242-248.
17. Milligan ED, Langer SJ, Sloane EM, etal. Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur J Neurosci. 2005;21(8):2136-2148.
18. Milligan ED, Soderquist RG, Malone SM, etal. Intrathecal polymer-based interleukin-10gene delivery for neuropathic pain. Neuron Glia Biol. 2006;2(4):293-308.
19. Ledeboer A, Jekich BM, Sloane EM, etal. Intrathecal interleukin-10gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun. 2007;21(5):686-698.
20. Sweitzer S, Martin D, DeLeo JA. Intrathecal interleukin-1 receptor antagonist in combination with soluble tumor necrosis factor receptor exhibits an anti-allodynic action in a rat model of neuropathic pain. Neuroscience. 2001;103(2):529-539.
21. Clark AK, D'Aquisto F, Gentry C, Marchand F, McMahon SB, Malcangio M. Rapid co-release of interleukin 1beta and caspase 1 in spinal cord inflammation. J Neurochem. 2006;99(3):868-880.
22. Milligan ED, O'Connor KA, Nguyen KT, etal. Intrathecal HIV-1 envelope glycoprotein gp120induces enhanced pain states mediated by spinal cord proinflammatory cytokines. J Neurosci. 2001;21(8):2808-2819.
23. Felts PA, Woolston AM, Fernando HB, etal. Inflammation and primary demyelination induced by the intraspinal injection of lipopolysaccharide. Brain. 2005;128(Pt 7):1649-1666.
24. Zhang RX, Li A, Liu B, etal. IL-1ra alleviates inflammatory hyperalgesia through preventing phosphorylation of NMDA receptor NR-1subunit in rats. Pain. 2008;135(3):232-239.
25. Liao YH, Zhang GH, Jia D, etal. Spinal astrocytic activation contributes to mechanical allodynia in a mouse model of type 2 diabetes. Brain Res. 2011;1368:324-335.
26. Ji XT, Qian NS, Zhang T, etal. Spinal astrocytic activation contributes to mechanical allodynia in a rat chemotherapy-induced neuropathic pain model. PLoS One. 2013;8(4):e60733.
27. DeLeo JA, Colburn RW, Rickman AJ. Cytokine and growth factor immunohistochemical spinal profiles in two animal models of mononeuropathy. Brain Res. 1997;759(1):50-57.
28. Sweitzer SM, Colburn RW, Rutkowski M, DeLeo JA. Acute peripheral inflammation induces moderate glial activation and spinal IL-1beta expression that correlates with pain behavior in the rat. Brain Res. 1999;829(1-2):209-221.
29. Gruber-Schoffnegger D, Drdla-Schutting R, Hönigsperger C, Wunderbaldinger G, Gassner M, Sandkühler J. Induction of thermal hyperalgesia and synaptic long-term potentiation in the spinal cord lamina I by TNF-α and IL-1β is mediated by glial cells. J Neurosci. 2013;33(15):6540-6551.
30. Whitehead KJ, Smith CG, Delaney SA, etal. Dynamic regulation of spinal pro-inflammatory cytokine release in the rat in vivo following peripheral nerve injury. Brain Behav Immun. 2010;24(4):569-576.
31. Alexander GM, van Rijn MA, van Hilten JJ, Perreault MJ, Schwartzman RJ. Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. Pain. 2005;116(3):213-219.
32. Backonja MM, Coe CL, Muller DA, Schell K. Altered cytokine levels in the blood and cerebrospinal fluid of chronic pain patients. J Neuroimmunol. 2008;195(1-2):157-163.
33. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell. 2002;10(2):417-426.
34. Thornberry NA, Bull HG, Calaycay JR, etal. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992;356(6372):768-774.
35. Ellis A, Bennett DL. Investigating the inflammasome within microglia and its modulation following nerve injury [abstract]. Ellis A, Bennett DL. International Association for the Study of Pain, 13th World Congress on Pain, Milan, Italy; 2012:PH373.
36. Kawasaki Y, Xu ZZ, Wang X, etal. Distinct roles of matrix metalloproteases in the early-and late-phase development of neuropathic pain. Nat Med. 2008;14(3):331-336.
37. Reeve AJ, Patel S, Fox A, Walker K, Urban L. Intrathecally administered endotoxin or cytokines produce allodynia, hyperalgesia and changes in spinal cord neuronal responses to nociceptive stimuli in the rat. Eur J Pain. 2000;4(3):247-257.
38. Sung CS, Wen ZH, Chang WK, etal. Intrathecal interleukin-1beta administration induces thermal hyperalgesia by activating inducible nitric oxide synthase expression in the rat spinal cord. Brain Res. 2004;1015(1-2):145-153.
39. Kawasaki Y, Zhang L, Cheng JK, Ji RR. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. J Neurosci. 2008;28(20): 5189-5194.
40. Liu T, Jiang CY, Fujita T, Luo SW, Kumamoto E. Enhancement by interleukin-1β of AMPA and NMDA receptor-mediated currents in adult rat spinal superficial dorsal horn neurons. Mol Pain. 2013;9:16.
41. Constandil L, Hernández A, Pelissier T, etal. Effect of interleukin-1beta on spinal cord nociceptive transmission of normal and monoarthritic rats after disruption of glial function. Arthritis Res Ther. 2009;11(4): R105.
42. Malcangio M, Bowery NG, Flower RJ, Perretti M. Effect of interleukin-1 beta on the release of substance P from rat isolated spinal cord. Eur J Pharmacol. 1996;299(1-3):113-118.
43. Wei F, Guo W, Zou S, Ren K, Dubner R. Supraspinal glial-neuronal interactions contribute to descending pain facilitation. J Neurosci. 2008;28(42):10482-10495.
44. Ishikawa T, Miyagi M, Kamoda H, etal. Differences between tumor necrosis factor-α receptors types 1 and 2in the modulation of spinal glial cell activation and mechanical allodynia in a rat sciatic nerve injury model. Spine (Phila Pa 1976). 2013;38(1):11-16.
45. Svensson CI, Schäfers M, Jones TL, Powell H, Sorkin LS. Spinal blockade of TNF blocks spinal nerve ligation-induced increases in spinal P-p38. Neurosci Lett. 2005;379(3):209-213.
46. Kiguchi N, Maeda T, Kobayashi Y, Kishioka S. Up-regulation of tumor necrosis factor-alpha in spinal cord contributes to vincristine-induced mechanical allodynia in mice. Neurosci Lett. 2008;445(2): 140-143.
47. Dogrul A, Gul H, Yesilyurt O, Ulas UH, Yildiz O. Systemic and spinal administration of etanercept, a tumor necrosis factor alpha inhibitor, blocks tactile allodynia in diabetic mice. Acta Diabetol. 2011;48(2): 135-142.
48. Marchand F, Tsantoulas C, Singh D, etal. Effects of Etanercept and Minocycline in a rat model of spinal cord injury. Eur J Pain. 2009;13(7): 673-681.
49. Nadeau S, Filali M, Zhang J, etal. Functional recovery after peripheral nerve injury is dependent on the pro-inflammatory cytokines IL-1β and TNF: implications for neuropathic pain. J Neurosci. 2011;31(35): 12533-12542.
50. DeLeo JA, Rutkowski MD, Stalder AK, Campbell IL. Transgenic expression of TNF by astrocytes increases mechanical allodynia in a mouse neuropathy model. Neuroreport. 2000;11(3):599-602.
51. Xu JT, Xin WJ, Zang Y, Wu CY, Liu XG. The role of tumor necrosis factor-alpha in the neuropathic pain induced by Lumbar 5 ventral root transection in rat. Pain. 2006;123(3):306-321.
52. Ohtori S, Takahashi K, Moriya H, Myers RR. TNF-alpha and TNF-alpha receptor type 1 upregulation in glia and neurons after peripheral nerve injury: studies in murine DRG and spinal cord. Spine (Phila Pa 1976). 2004;29(10):1082-1088.
53. Hao S, Mata M, Glorioso JC, Fink DJ. Gene transfer to interfere with TNFalpha signaling in neuropathic pain. Gene Ther. 2007;14(13): 1010-1016.
54. Youn DH, Wang H, Jeong SJ. Exogenous tumor necrosis factor-alpha rapidly alters synaptic and sensory transmission in the adult rat spinal cord dorsal horn. J Neurosci Res. 2008;86(13):2867-2875.
55. Park CK, Lü N, Xu ZZ, Liu T, Serhan CN, Ji RR. Resolving TRPV1-and TNF-α-mediated spinal cord synaptic plasticity and inflammatory pain with neuroprotectin D1. J Neurosci. 2011;31(42):15072-15085.
56. Zhang L, Berta T, Xu ZZ, Liu T, Park JY, Ji RR. TNF-α contributes to spinal cord synaptic plasticity and inflammatory pain: distinct role of TNF receptor subtypes 1 and 2. Pain. 2011;152(2):419-427.
57. Schäfers M, Sommer C, Geis C, Hagenacker T, Vandenabeele P, Sorkin LS. Selective stimulation of either tumor necrosis factor receptor differentially induces pain behavior in vivo and ectopic activity in sensory neurons in vitro. Neuroscience. 2008;157(2):414-423.
58. Liu YL, Zhou LJ, Hu NW, etal. Tumor necrosis factor-alpha induces long-term potentiation of C-fiber evoked field potentials in spinal dorsal horn in rats with nerve injury: the role of NF-kappa B, JNK and p38 MAPK. Neuropharmacology. 2007;52(3):708-715.
59. Gao YJ, Zhang L, Samad OA, etal. JNK-induced MCP-1 production in spinal cord astrocytes contributes to central sensitization and neuropathic pain. J Neurosci. 2009;29(13):4096-4108.
60. Gao YJ, Zhang L, Ji RR. Spinal injection of TNF-α-activated astrocytes produces persistent pain symptom mechanical allodynia by releasing monocyte chemoattractant protein-1. Glia. 2010;58(15):1871-1880.
61. Bajetto A, Bonavia R, Barbero S, Schettini G. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. J Neurochem. 2002;82(6):1311-1329.
62. Réaux-Le Goazigo A, Van Steenwinckel J, Rostène W, Mélik Parsadaniantz S. Current status of chemokines in the adult CNS. Prog Neurobiol. 2013;104:67-92.
63. Bazan JF, Bacon KB, Hardiman G, etal. A new class of membrane-bound chemokine with a CX3C motif. Nature. 1997;385(6617):640-644.
64. Pan Y, Lloyd C, Zhou H, etal. Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature. 1997;387(6633): 611-617.
65. Imai T, Hieshima K, Haskell C, etal. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell. 1997;91(4):521-530.
66. Clark AK, Yip PK, Grist J, etal. Inhibition of spinal microglial cathepsin S for the reversal of neuropathic pain. Proc Natl Acad Sci U S A. 2007;104(25):10655-10660.
67. Clark AK, Staniland AA, Malcangio M. Fractalkine/CX3CR1signalling in chronic pain and inflammation. Curr Pharm Biotechnol. 2011;12(10):1707-1714.
68. Fong AM, Robinson LA, Steeber DA, etal. Fractalkine and CX3CR1mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med. 1998;188(8): 1413-1419.
69. Corcione A, Ferretti E, Bertolotto M, etal. CX3CR1 is expressed by human B lymphocytes and mediates [corrected] CX3CL1 driven chemotaxis of tonsil centrocytes. PLoS One. 2009;4(12):e8485.
70. Lindia JA, McGowan E, Jochnowitz N, Abbadie C. Induction of CX3CL1 expression in astrocytes and CX3CR1in microglia in the spinal cord of a rat model of neuropathic pain. J Pain. 2005;6(7):434-438.
71. Clark AK, Yip PK, Malcangio M. The liberation of fractalkine in the dorsal horn requires microglial cathepsin S. J Neurosci. 2009;29(21): 6945-6954.
72. Verge GM, Milligan ED, Maier SF, Watkins LR, Naeve GS, Foster AC. Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur J Neurosci. 2004;20(5):1150-1160.
73. Kim KW, Vallon-Eberhard A, Zigmond E, etal. In vivo structure/function and expression analysis of the CX3C chemokine fractalkine. Blood. 2011;118(22):e156-e167.
74. Zhuang ZY, Kawasaki Y, Tan PH, Wen YR, Huang J, Ji RR. Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine. Brain Behav Immun. 2007;21(5):642-651.
75. Jung S, Aliberti J, Graemmel P, etal. Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. Mol Cell Biol. 2000;20(11):4106-4114.
76. Clark AK, Wodarski R, Guida F, Sasso O, Malcangio M. Cathepsin S release from primary cultured microglia is regulated by the P2X7 receptor. Glia. 2010;58(14):1710-1726.
77. Milligan E, Zapata V, Schoeniger D, etal. An initial investigation of spinal mechanisms underlying pain enhancement induced by fractalkine, a neuronally released chemokine. Eur J Neurosci. 2005;22(11): 2775-2782.
78. Owolabi SA, Saab CY. Fractalkine and minocycline alter neuronal activity in the spinal cord dorsal horn. FEBS Lett. 2006;580(18): 4306-4310.
79. Clark AK, Marchand F, D'Auria M etal. Cathepsin S inhibiton attenuates neuropathic pain and microglial response associated with spinal cord injury. Open Pain J. 2010;3:117-122.
80. Clark AK, Grist J, Al-Kashi A, Perretti M, Malcangio M. Spinal cathepsin S and fractalkine contribute to chronic pain in the collagen-induced arthritis model. Arthritis Rheum. 2012;64(6):2038-2047.
81. Milligan ED, Zapata V, Chacur M, etal. Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur J Neurosci. 2004;20(9):2294-2302.
82. Sun JL, Xiao C, Lu B, etal. CX3CL1/CX3CR1 regulates nerve injury-induced pain hypersensitivity through the ERK5signaling pathway. J Neurosci Res. 2013;91(4):545-553.
83. Staniland AA, Clark AK, Wodarski R, etal. Reduced inflammatory and neuropathic pain and decreased spinal microglial response in fractalkine receptor (CX3CR1) knockout mice. J Neurochem. 2010;114(4): 1143-1157.
84. Wolf Y, Yona S, Kim KW, Jung S. Microglia, seen from the CX3CR1 angle. Front Cell Neurosci. 2013;7:26.
85. Van Coillie E, Van Damme J, Opdenakker G. The MCP/eotaxin subfamily of CC chemokines. Cytokine Growth Factor Rev. 1999;10(1): 61-86.
86. Gao YJ, Ji RR. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther. 2010;126(1):56-68.
87. Dansereau MA, Gosselin RD, Pohl M, etal. Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonist-treated rats. J Neurochem. 2008;106(2):757-769.
88. Jeon SM, Lee KM, Cho HJ. Expression of monocyte chemoattractant protein-1in rat dorsal root ganglia and spinal cord in experimental models of neuropathic pain. Brain Res. 2009;1251:103-111.
89. Thacker MA, Clark AK, Bishop T, etal. CCL2 is a key mediator of microglia activation in neuropathic pain states. Eur J Pain. 2009;13(3): 263-272.
90. Van Steenwinckel J, Reaux-Le Goazigo A, Pommier B etal. CCL2 released from neuronal synaptic vesicles in the spinal cord is a major mediator of local inflammation and pain after peripheral nerve injury. J Neurosci. 2011;31(15):5865-5875.
91. Abbadie C, Lindia JA, Cumiskey AM, etal. Impaired neuropathic pain responses in mice lacking the chemokine receptor CCR2. Proc Natl Acad Sci U S A. 2003;100(13):7947-7952.
92. Gosselin RD, Varela C, Banisadr G, etal. Constitutive expression of CCR2 chemokine receptor and inhibition by MCP-1/CCL2 of GABA-induced currents in spinal cord neurones. J Neurochem. 2005;95(4): 1023-1034.
93. Knerlich-Lukoschus F, Juraschek M, Blömer U, Lucius R, Mehdorn HM, Held-Feindt J. Force-dependent development of neuropathic central pain and time-related CCL2/CCR2 expression after graded spinal cord contusion injuries of the rat. J Neurotrauma. 2008;25(5):427-448.
94. Jung H, Bhangoo S, Banisadr G, etal. Visualization of chemokine receptor activation in transgenic mice reveals peripheral activation of CCR2 receptors in states of neuropathic pain. J Neurosci. 2009;29(25): 8051-8062.
95. Tanaka T, Minami M, Nakagawa T, Satoh M. Enhanced production of monocyte chemoattractant protein-1in the dorsal root ganglia in a rat model of neuropathic pain: possible involvement in the development of neuropathic pain. Neurosci Res. 2004;48(4):463-469.
96. Pevida M, Lastra A, Hidalgo A, Baamonde A, Menéndez L. Spinal CCL2 and microglial activation are involved in paclitaxel-evoked cold hyperalgesia. Brain Res Bull. 2013;95:21-27.
97. Serrano A, Paré M, McIntosh F, etal. Blocking spinal CCR2 with AZ889 reversed hyperalgesia in a model of neuropathic pain. Mol Pain. 2010;6:90.
98. Kalliomäki J, Attal N, Jonzon B, etal; AZD2423 PTN Study Group. A randomized, double-blind, placebo-controlled trial of a chemokine receptor 2 (CCR2) antagonist in posttraumatic neuralgia. Pain. 2013;154(5):761-767.
99. Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008;226:205-218.
100. Saraiva M, O'Garra A. The regulation of IL-10 production by immune cells. Nat Rev Immunol. 2010;10(3):170-181.
101. Iyer SS, Cheng G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol. 2012;32(1):23-63.
102. Hulshof S, Montagne L, De Groot CJ, Van Der Valk P. Cellular localization and expression patterns of interleukin-10, interleukin-4, and their receptors in multiple sclerosis lesions. Glia. 2002;38(1):24-35.
103. Ledeboer A, Wierinckx A, Bol JG, etal. Regional and temporal expression patterns of interleukin-10, interleukin-10 receptor and adhesion molecules in the rat spinal cord during chronic relapsing EAE. J Neuroimmunol. 2003;136(1-2):94-103.
104. Alexander GM, Perreault MJ, Reichenberger ER, Schwartzman RJ. Changes in immune and glial markers in the CSF of patients with Complex Regional Pain Syndrome. Brain Behav Immun. 2007;21(5):668-676.
105. Milligan ED, Penzkover KR, Soderquist RG, Mahoney MJ. Spinal interleukin-10 therapy to treat peripheral neuropathic pain. Neuromodulation. 2012;15(6):520-526; discussion 526-.
106. Soderquist RG, Milligan ED, Harrison JA, etal. PEGylation of interleukin-10 for the mitigation of enhanced pain states. J Biomed Mater Res A. 2010;93(3):1169-1179.
107. Milligan ED, Sloane EM, Langer SJ, etal. Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol Pain. 2005;1:9.
108. Milligan ED, Sloane EM, Langer SJ, etal. Repeated intrathecal injections of plasmid DNA encoding interleukin-10 produce prolonged reversal of neuropathic pain. Pain. 2006;126(1-3):294-308.
109. Soderquist RG, Sloane EM, Loram LC, etal. Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration. Pharm Res. 2010;27(5):841-854.
110. Gadani SP, Cronk JC, Norris GT, Kipnis J. IL-4in the brain: a cytokine to remember. J Immunol. 2012;189(9):4213-4219.
111. Jiang H, Harris MB, Rothman P. IL-4/IL-13signaling beyond JAK/STAT. J Allergy Clin Immunol. 2000;105(6 Pt 1):1063-1070.
112. Üçeyler N, Topuzoǧlu T, Schiesser P, Hahnenkamp S, Sommer C. IL-4 deficiency is associated with mechanical hypersensitivity in mice. PLoS One. 2011;6(12):e28205.